Tony S. Mok
Affiliations: | Medical Sciences | The Chinese University of Hong Kong, Hong Kong, Hong Kong |
Area:
Oncology, Microbiology BiologyGoogle:
"Tony Mok"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Garon EB, Cho BC, Luft A, et al. (2024) A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. Clinical Lung Cancer |
| Cheung AH, Wong KY, Chau SL, et al. (2024) SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant. Pathology |
| Dziadziuszko R, Peled N, Mok T, et al. (2024) High-dose alectinib for fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. Contemporary Oncology (Poznan, Poland). 27: 217-223 |
| Mok T, Nakagawa K, Park K, et al. (2024) Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301017 |
| Gridelli C, Peters S, Mok T, et al. (2023) Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer (Amsterdam, Netherlands). 187: 107441 |
| Mok T, Jänne PA, Nishio M, et al. (2023) HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced -mutated NSCLC after a third-generation EGFR TKI. Future Oncology (London, England) |
| Garon EB, Cho BC, Luft A, et al. (2023) Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer (Amsterdam, Netherlands). 186: 107422 |
| Sequist LV, Yang JC, Yamamoto N, et al. (2023) Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 2869-2876 |
| Zhou Q, Soo RA, Chang GC, et al. (2023) Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced -Positive NSCLC. Jto Clinical and Research Reports. 4: 100499 |
| Chmielecki J, Mok T, Wu YL, et al. (2023) Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature Communications. 14: 1071 |